International Valuation Protocol for the EQ-5D-Y-3L Juan M. Ramos-GoñiMark OppeNancy Devlin Practical Application Open access 16 April 2020 Pages: 653 - 663
Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations Matthew FranklinJames LomasGerry Richardson Review Article Open access 15 April 2020 Pages: 665 - 681
Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review Koen DegelingMartin VuMaarten IJzerman Systematic Review 22 April 2020 Pages: 683 - 713
Economic Costs of Myasthenia Gravis: A Systematic Review Erik LandfeldtOksana PogoryelovaHanns Lochmüller Systematic Review Open access 04 May 2020 Pages: 715 - 728
Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice? Audrey A. TranVinay Prasad Commentary 24 April 2020 Pages: 729 - 731
What Value Does the NCCN Affordability Rating Really Provide to Patients, Providers, and Society? R. Brett McQueen Commentary 15 May 2020 Pages: 733 - 735
The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability Rating Aaron P. MitchellPranammya DeyPeter B. Bach Original Research Article 23 March 2020 Pages: 737 - 745
Cost-Effectiveness Analysis of Patiromer in Combination with Renin–Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden Julia WidénMagnus IvarssonC. Simone Sutherland Original Research Article 02 April 2020 Pages: 747 - 764
R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study Rose HartDarren BurnsDawn Lee Original Research Article 31 March 2020 Pages: 765 - 776